S&P Futures
4,030.25 +28.75 (+0.72%) Dow Futures
32,749.00 +161.00 (+0.49%) Nasdaq Futures
12,829.25 +96.75 (+0.76%) Russell 2000 Futures
1,780.70 +15.90 (+0.90%) Crude Oil
73.71 +0.51 (+0.70%) Gold
1,962.50 -11.00 (-0.56%)
Citius Pharmaceuticals, Inc. (47N.F)
Chart Events
Performance Outlook
| Previous Close | 0.9348 |
| Open | 0.9453 |
| Bid | 0.9461 x N/A |
| Ask | 0.9726 x N/A |
| Day's Range | 0.9453 - 0.9453 |
| 52 Week Range | 0.7251 - 1.6798 |
| Volume | |
| Avg. Volume | 195 |
| Market Cap | 141.54M |
| Beta (5Y Monthly) | 1.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3870 |
| Earnings Date | May 10, 2023 - May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- Simply Wall St.
When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven?
Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would...
- PR Newswire
Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB.
- PR Newswire
Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in the 35th Annual Roth Conference being held March 12-14, 2023 in Dana Point, California. Citius Chairman and CEO Leonard Mazur will host one-on-one meetings with institutional investors and analysts on Monday, March 13th and Tuesday, March 14th.
